Trials Sponsors Conditions Drugs Pricing

Conditions

ADHD, ADD

Keywords

ADHD, children, CADS-T, Dexmethylphenidate-HCl, extended release

Outcome Measures

Primary Outcomes (1)

Assessment of the symptoms by the patient's teacher after 5 weeks of treatment.

Secondary Outcomes (4)

Assessment of the symptoms by the patient's parent after five weeks of treatment.
Change in severity of the illness assessed by the physician after 5 weeks of treatment
Improvement of the illness assessed by the physician after 5 weeks of treatment
Safety and tolerability of 5 week's treatment with dexmethylphenidate HCl extended-release capsules in children with Attention-Deficit/Hyperactivity Disorder by assessing the frequency of adverse findings

Interventions

Dexmethylphenidate HCl extended-release capsulesDrug

Registry intervention entries

These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.

Formulated product
Dexmethylphenidate HCl extended-release capsules
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
View registry record

Eligibility Criteria

Age6 Years - 12 Years

Sexall

Age GroupsChild (0-17)

You may qualify if:

Children 6 - 12 with a diagnosis of ADHD of any type , Same teacher who is willing to complete the assessment during the school term

You may not qualify if:

Sponsors & Collaborators

Novartis
Industrylead

Study Sites (25)

Novartis Investigational Site

Mesa, Arizona, 85210, United States

Novartis Investigational Site

Little Rock, Arkansas, 72205, United States

Novartis Investigational Site

Los Angeles, California, 90095, United States

Novartis Investigational Site

Boulder, Colorado, 80304, United States

Novartis Investigational Site

Maitland, Florida, 32751, United States

Novartis Investigational Site

Orlando, Florida, 32806, United States

Novartis Investigational Site

Stone Mountain, Georgia, 30083, United States

MeSH Terms

Conditions

Attention Deficit Disorder with Hyperactivity

Condition Hierarchy (Ancestors)

Attention Deficit and Disruptive Behavior DisordersNeurodevelopmental DisordersMental Disorders

Study Officials

Novartis Pharmaceuticals
Novartis Pharmaceuticals
STUDY CHAIR

Study Design

Study Type: interventional
Phase: phase 3
Allocation: RANDOMIZED
Masking: DOUBLE
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: INDUSTRY

Study Record Dates

First Submitted

March 8, 2006

First Posted

March 10, 2006

Study Start

February 2006

Date type not reported

This date has not been verified as actual or estimated.

Study Completion

November 2006

Actual (reported)

Efficacy, Tolerability and Safety of Dexmethylphenidate HCl Extended-Release Capsules in Children With Attention-Deficit/Hyperactivity Disorder

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (4)

Interventions

Registry intervention entries

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (25)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (4)

Interventions

Registry intervention entries

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (25)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

Source record

Locations